Unasyn and Relafen drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Unasyn (ampicillin sodium; sulbactam sodium) and Relafen (nabumetone). Common drug interactions include laryngospasm among females and hepatitis among males.

The phase IV clinical study analyzes what interactions people have when they take Unasyn and Relafen. It is created by eHealthMe based on reports of 27 people who take the same drugs from the FDA, and is updated regularly.

What is Unasyn?

Unasyn has active ingredients of ampicillin sodium; sulbactam sodium. eHealthMe is studying from 4,474 Unasyn users. Check the latest studies of Unasyn.

What is Relafen?

Relafen has active ingredients of nabumetone. It is often used in arthritis. eHealthMe is studying from 6,243 Relafen users. Check the latest studies of Relafen.

On Aug, 07, 2026

27 people who take Unasyn and Relafen together, and have interactions are studied.

What are the common drug interactions of Unasyn and Relafen, by gender? *:

female:

Laryngospasm (an uncontrolled/involuntary muscular contraction of larynx)
Leukopenia (less number of white blood cells in blood)
Mitral valve sclerosis (thickening and stiffness of the valve)
Monoclonal immunoglobulin present
Mouth ulceration (mouth ulcers)
Muscle spasms (muscle contraction)
Neck pain
Non-cardiac chest pain
Oral fungal infection
Reflux gastritis (a condition in which the lining of a person's stomach becomes inflamed as a result of exposure to bile)

male:

Hepatitis (inflammation of the liver)
White blood cell count increased
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Drug hypersensitivity
Headache (pain in head)
Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
Hepatic failure (liver failure)
Hepatic neoplasm malignant (liver cancer)
Hepatitis viral

What are the common drug interactions of Unasyn and Relafen, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Deformity (disfigurement)
Depression
Discomfort
Emotional distress
Fall
Hypophagia (reduced food intake)
Injury
Musculoskeletal chest pain (pain in chest muscle or nerve or bones)
Neuropathy peripheral (surface nerve damage)
Rectal haemorrhage (bleeding from anus)

60+:

Abdominal discomfort
Adenoma benign (non-cancerous tumour -secreting)
Bone pain
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cardiac failure congestive
Cataract (clouding of the lens inside the eye)
Chills (felling of cold)
Comminuted fracture (bone has broken into several pieces)
Compression fracture (fracture due to pressure caused by injury)
Deformity (disfigurement)

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 20 people, 74.07%
Upper Respiratory Tract Infection: 11 people, 40.74%
Restless Leg Syndrome (a powerful urge to move your legs): 11 people, 40.74%
Pain: 11 people, 40.74%
Muscle Spasms (muscle contraction): 11 people, 40.74%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 11 people, 40.74%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 10 people, 37.04%
Anaemia (lack of blood): 10 people, 37.04%

* Approximation only. Some reports may have incomplete information.

Do you take Unasyn and Relafen?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously